Most programs that stall don’t stall because the molecule failed. They stall because regulatory, CMC, quality, and nonclinical decisions were made one after another instead of together.
Ask a development team why a milestone slipped, and you’ll rarely hear “the science didn’t work.” You’ll hear that the tox batch didn’t match the clinical batch. Or that the specifications didn’t hold up to the regulatory strategy. Or that the CDMO’s quality system wasn’t ready when the first GMP lot was.
These aren’t scientific failures. They’re sequencing failures. And they are some of the most expensive and most avoidable problems in drug development.
The Relay-Race Problem
Most development plans are built like a relay race. Nonclinical sets the tox program. CMC scales a process to supply it. Regulatory writes a strategy around what’s already been done. Quality comes in to audit the result.
Each handoff looks efficient on its own. Each function is doing good work in its own lane. The trouble is that every decision quietly constrains the next one, and nobody is looking at all of them at once.
By the time the gaps surface, usually during IND preparation, a pre-submission meeting, or diligence, the cheapest moment to fix them has passed.
What the Record Shows
We no longer have to guess how often this happens. In July 2025, the FDA published more than 200 complete response letters (CRLs) for drugs and biologics, with the stated aim of reducing the “guessing game” for developers and investors.
When Pharma Manufacturing analyzed those letters, it found that 150 of the 202 CRLs issued from 2020 through 2024, or 74%, involved quality or manufacturing issues. That includes problems with manufacturing processes, facility inspections, and CMC.
Here’s the telling part: that first release covered products the FDA later approved. The science held up. The delay came from somewhere else.
And those problems don’t start at the marketing application. As one CMC regulatory leader wrote in March 2026, they “rarely emerge suddenly; instead, they originate from development choices made during preclinical and early clinical phases.” In other words, the late-stage problem is usually an early-stage sequencing decision.
Where Sequencing Breaks a Plan
The failure points tend to sit exactly where one function hands off to the next:
- Nonclinical → CMC. The tox study runs on material from an early process. The process changes before first-in-human. Now the program has a comparability question it didn’t plan for.
- CMC → Regulatory. Specifications and analytical methods are set before anyone has defined what’s phase-appropriate for the filing strategy. They’re either too loose to defend or too tight to meet.
- Quality → CMC. The quality agreement, supplier qualification, and batch-release approach arrive after the first GMP campaign is already scheduled.
- Clinical supply → Clinical. Drug product timing and labeling are planned after the protocol, so the first patient waits on the first vial.
- Strategy → Vendors. The CDMO or CRO is chosen before the plan exists, and the plan bends to fit that vendor’s capacity instead of the program’s needs.
None of these is exotic. Each one is a reasonable decision made at the wrong time, without the other functions at the table.
Why This Is a Board Problem, Not Just a Technical One
For a Series B–D company, a sequencing gap doesn’t stay in the lab. It shows up as a missed milestone, a bridge round, or a harder conversation in diligence.
The financing environment makes that more costly. J.P. Morgan’s Q2 2026 biopharma deal report found that upfront cash made up just 6% of total licensing deal value in the first half of 2026, with deal structures leaning heavily on milestones. When most of a deal’s value is tied to future milestones, a plan that can’t reliably hit them is a valuation problem.
And now that CRLs are public, investors and partners can see exactly where programs like yours have stumbled. A development plan has to hold up to that scrutiny, not just to the next internal review.
What Deciding Together Looks Like
Fixing this doesn’t mean more meetings. It means building the plan so the cross-functional decisions are visible and made on purpose. In practice, that looks like:
- One roadmap, every function. Clinical, nonclinical, CMC, regulatory, quality, clinical supply, medical writing, and governance on a single timeline, so a change in one lane shows its impact on the others.
- Decisions placed where functions meet. Material for tox, phase-appropriate specifications, and quality systems are scheduled as joint decisions, not handoffs.
- Gates judged across every function. Readiness for an IND, a pivotal start, or a partnering process is assessed against all the workstreams that feed it, not only the one that owns the deadline.
- Strategy before vendors. The plan defines what the program needs. CDMO and CRO selection follows from it.
A useful test: pick your next named milestone and ask who decided each of the inputs it depends on, and when. If the answer is “different people, at different times, without each other,” the risk is in the sequencing.
How Syner-G Helps
Removing the barriers between functions and phases is what Syner-G was built to do. As a strategic development and delivery partner, we bring science, strategy, and delivery under one roof. Our Scientific, Regulatory & Quality experts cover regulatory strategy, CMC, quality systems, discovery sciences, and medical writing, and they plan together from the start. Whether you’re an emerging biotech working toward your first IND or a team preparing for approval, we help you build a plan that anticipates challenges and holds up at every gate. And because the plan comes first, your CDMO and CRO choices follow from what your program needs, not the other way around.
Build the Plan Your Board Can Defend
The Integrated Development Roadmap Playbook walks through how to build a development plan where regulatory, CMC, quality, and nonclinical decisions are made together. It includes the swim lane framework and a planning template you can use with your team.
